Oxypaeoniflorin

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

氧芍药甙是从赤芍和白芍中提取的天然产物。

Oxypaeoniflorin is a natural product derived from Radix Paeoniae Rubra and Radix Paeoniae Alba.

Oxypaeoniflorin (OPA; 0.1-10 μM; 8 hours) obviously reversed the hypoxia/reoxygenation (H/R)-induced decrease in cell activity and increase in apoptosis of H9c2 cells. Oxypaeoniflorin inhibits apoptosis by activating the Sirt1 (silent information regulator factor 2 related enzyme 1)/Foxo1(forkhead transcription factor FKHR) signaling pathway in myocardial tissues and H9c2 cells. Oxypaeoniflorin (0-30 μM) attenuates inflammatory effects via regulation of the toll-like receptor (TLR), extracellular signal-related kinase (ERK) and p38 mitogen-activated protein (MAP) kinases signaling pathways in LPS-stimulated RAW264.7 cells.

Oxypaeoniflorin (OPA; 10-40 mg/kg; intragastrical administration; every day; for 30 days) treatment significantly reduces disruption of cardiac function and improves the indicators of ejection fraction (EF) and fractional shortening (FS). Oxypaeoniflorin significantly reduces the release of myocardial infarction-related factors, such as the creatine kinase (CK-MB), cardiac troponin I (cTnI) and cardiac troponin T (cTnT). Animal Model: C57BL/6 male mice (6-8 weeks of age, 20-25 g) bearing myocardial ischemia/reperfusion (MI/R) injury Dosage:10 mg/kg, 20 mg/kg, 40 mg/kg Administration:Intragastrical administration; every day; for 30 days Result:Significantly reduced disruption of cardiac function and improved the indicators of ejection fraction (EF) and fractional shortening (FS).

——

Others

Other Targets

Others

Others-Field

——

39011-91-1

496.46

C23H28O12

>98% (HPLC)

DMSO : 100 mg/mL 201.43 mM

C[C@]12C[C@@]3([C@@H]4C[C@]1([C@@]4([C@H](O2)O3)COC(=O)c1ccc(cc1)O)O[C@H]1[C@@H]([C@H]([C@@H]([C@H](O1)CO)O)O)O)O

——

(-20℃)

With Ice Pack

≥ 2 years